Formosa Laboratories Executive and Leadership Team

Chih-Ping Yang, the Chief Executive Officer at Formosa Laboratories, directs the overarching corporate strategy and long-term vision for the organization. By aligning manufacturing capabilities with international regulatory requirements from the US FDA and EDQM, the Chief Executive Officer ensures consistent market access for Vitamin D derivatives and specialty chemicals. Chih-Ping Yang manages high-level relationships with global health authorities to maintain GMP compliance across all modern facilities. This leadership role involves evaluating capital investments in production technology to optimize output efficiency. By prioritizing quality control and regulatory excellence, the Chief Executive Officer secures the company's position as a premier global supplier. Through constant monitoring of industry trends, the Chief Executive Officer drives sustainable growth and operational stability. Ultimately, the Chief Executive Officer fosters a culture of precision and innovation that defines the company's reputation in the pharmaceutical manufacturing sector.

Chen-Yu Cheng, the President at Formosa Laboratories, oversees internal operations and the execution of large-scale API production schedules. Focusing on the manufacturing of UV-filters like avobenzone and Octinoxate, the President optimizes facility throughput to meet global demand. Chen-Yu Cheng coordinates with technical teams to ensure that process development aligns with strict quality standards. This leadership role requires managing complex supply chains and resource allocation to maintain consistent production cycles. By streamlining internal workflows, the President enhances operational efficiency across the Taoyuan facilities. The President monitors performance metrics to identify areas for process improvement and cost reduction. Through rigorous oversight of daily manufacturing activities, the President guarantees that all products meet the stringent requirements of international regulatory bodies. Ultimately, the President maintains the operational integrity necessary for the company to deliver reliable pharmaceutical ingredients to clients worldwide.

C.P. Yang, the President at Formosa Laboratories, manages the custom synthesis service division and client-facing technical documentation support. By architecting specialized workflows for process development, the President enables the transition of complex chemical compounds from laboratory scale to full commercial production. C.P. Yang ensures that all custom synthesis projects adhere to the same high GMP standards that define the company's core API portfolio. This leadership role involves collaborating with pharmaceutical partners to provide tailored chemical solutions that meet specific therapeutic needs. By overseeing the documentation team, the President guarantees that every project receives the necessary regulatory support for global market entry. C.P. Yang drives the expansion of the company's service capabilities to attract new international partnerships. Through meticulous attention to technical detail, the President secures the company's reputation as a trusted partner for specialty chemical development and manufacturing.

C.Y. Cheng, the President at Formosa Laboratories, directs the strategic expansion of the company's market reach across diverse geographic regions. By analyzing international demand for APIs like Montelukast and Sevelamer, the President identifies key growth opportunities in emerging pharmaceutical markets. C.Y. Cheng coordinates with the sales and marketing departments to align product availability with regional regulatory approvals from the PMDA and other global agencies. This leadership role involves assessing competitive landscapes to refine the company's commercial approach. By fostering strong relationships with international distributors, the President ensures the effective distribution of the company's product portfolio. C.Y. Cheng monitors market shifts to adjust production priorities and maintain a competitive edge. Through strategic planning and market analysis, the President supports the company's objective of becoming a dominant force in the global API manufacturing industry while maintaining high standards of quality and reliability.